About this study
This study will look at how well 2 medicines treat SMARCB1- and SMARCA4-deficient tumors. The cells in SMARCB1- and SMARCA4-deficient tumors lack SMARCB1 and SMARCA4 genes. These genes are present in certain types of cancers that are hard to treat.
The medicines in this study are tiragolumab and atezolizumab. They are a type of immunotherapy, which helps the body’s own immune system fight cancer.
We will study how well these drugs work in children and young adults whose cancer has come back or did not respond to treatment.
There are 2 phases, or parts, to this clinical trial:
- Phase 1 (or Part A) helps us decide the best dose of tiragolumab to use in children. Patients enrolled in phase 1 may be treated with tiragolumab along with atezolizumab at a later time. Once a safe dose is found in phase 1, these patients can enroll in phase 2 of the clinical trial.
- Phase 2 (or Part B) is open to people 18 years and older. We will study how well tiragolumab and atezolizumab work in treating 6 kinds of cancer in young adults:
- Renal medullary carcinoma
- Malignant rhabdoid tumor
- Atypical teratoid rhabdoid tumor
- Poorly differentiated chordoma
- Epithelioid sarcoma
- Other SMARCB1- or SMARCA4-deficient tumors
Purpose of this clinical trial
- Find the best dose of tiragolumab to use in children.
- Determine how well tiragolumab and atezolizumab treat children, teens, and young adults with SMARCB1- or SMARCA4-deficient tumors that have come back or did not respond to therapy.
Eligibility overview
To take part in this study, you must:
- Have a SMARCB1- or SMARCA4-deficient tumor that has come back or did not respond to therapy
- Be 1–17 years old for phase 1
- Be 18 years old or older for phase 2